chevron_leftBack
As of 13 June 2026, Goldenwell Biotech, Inc. has a market cap of $99.0M USD, ranking #25626 globally and #3945 in the United States.
It ranks #2295 in the Healthcare sector, and #121 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$99.0MUSD
Enterprise Value
$99.23MUSD
Revenue (TTM)
$62.34KUSD
Net Income (TTM)
-$75.12KUSD
Profit Margin
-120%
PS Ratio
1588.0
PB Ratio
-1044.1
Company Profile
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.4% | -48% | -4.8% | -64% | 400% | 400% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
GWLL
Goldenwell Biotech Inc Ordinary Shares
ISIN: US38138N1046
Shares Out.:
Shares Outstanding:
99.0M1
Shares Float:
36.0M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Goldenwell Biotech, Inc.
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: RVMD
|
$29.56B
30K%
|
-
|
|
LSE: INDV
|
$2.07B
2K%
1.54B GBP
|
-
|
|
OTCMKTS: NDOI
|
$1.8B
2K%
|
0.4
|
|
NASDAQ: DVAX
|
$1.76B
2K%
|
-
|
|
NASDAQ: AVBP
|
$1.33B
1K%
|
-
|
|
NYSE: BRBR
|
$1.02B
935%
|
12.1
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
TLV: TEVA
|
$36.75B
37K%
108.92B ILS
|
24.2
|
|
SHE: 002001
|
$15.84B
16K%
107.34B CNY
|
16.0
|
|
NSE: CIPLA
|
$11.16B
11K%
1.06T INR
|
23.4
|
|
NSE: LUPIN
|
$11.04B
11K%
1.05T INR
|
22.7
|
|
SHE: 002653
|
$9.09B
9K%
61.6B CNY
|
80.6
|
|
EPA: ABVX
|
$8.74B
9K%
7.57B EUR
|
-
|
chevron_leftBack